Fig. 2: Comparisons of viral burden at treatment initiation (5 DPI) by treatment cohort and clinical outcome. | Nature Communications

Fig. 2: Comparisons of viral burden at treatment initiation (5 DPI) by treatment cohort and clinical outcome.

From: Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus

Fig. 2

EBOV vRNA abundance and circulating viremia was assessed at the time of treatment initiation (5 DPI) for each animal in each treatment cohort. a, b Comparison of EBOV vRNA abundance (a) and circulating live virus (b) at 5 DPI by treatment cohort. c, d Comparison of EBOV vRNA abundance (c) and circulating live virus at 5 DPI (d) by clinical outcome (“survivor” or “fatal”). For all panels, bars represent the geometric mean ± geometric SD for each group. For (a, b) individual animals are represented by color-coded symbols within bars. For (a, b) statistical comparison was performed by non-parametric ANOVA (Kruskal-Wallis test) followed by Dunn’s post-hoc test for multiple comparisons. For (c, d) significance was determined by non-parametric Mann–Whitney U-test. All reported p-values are two-tailed. For all panels, individual data points represent the mean of two technical replicates. Dashed horizontal lines indicate the lower limit of quantitation (LLOQ) for the assay (1000 GEq/mL for RT-qPCR; 25 PFU/mL for plaque titration, where GEq = genome equivalents).

Back to article page